Kelonia Therapeutics, Inc. is a clinical-stage biotechnology company based in Boston, Massachusetts, focused on developing in vivo gene delivery technologies for genetic medicines. Founded around 2021, it pioneered the in vivo gene placement system (iGPS®), utilizing engineered lentiviral particles with envelope and tropism modifications to selectively target T cells and generate CAR-T cells directly in the body.
The company's lead candidate, KLN-1010, is a one-time intravenous anti-BCMA CAR-T therapy in Phase 1 trials (inMMyCAR study) for relapsed/refractory multiple myeloma. Early clinical data presented at the 2025 ASH Annual Meeting demonstrated potential efficacy, including minimal residual disease-negative outcomes.
With an initial emphasis on hematologic cancers and solid tumors, Kelonia aims to expand its pipeline across various diseases, enabling off-the-shelf treatments without ex vivo manufacturing or lymphodepleting chemotherapy. In April 2026, Eli Lilly agreed to acquire Kelonia for up to $7 billion, including $3.25 billion upfront, to advance these in vivo CAR-T therapies; the deal is expected to close in the second half of 2026, subject to approvals.
To provide comprehensive coverage, we aggregate data and news under the name Kelonia, encompassing the following company names, divisions, and related entities:
Kelonia Therapeutics.
This list encompasses current and former names, alternate names, and key divisions associated with Kelonia, ensuring you can easily find all relevant information under a single, unified profile.
